炎症性肠病合并直肠癌患者盆腔放疗结局的配对病例对照分析
该配对病例对照分析纳入2000至2015年诊断的186例美国退伍军人直肠癌患者,比较接受放疗的IBD患者与无IBD对照的毒性与死亡结局。结果显示放疗期间中断、止泻药需求无差异,IBD组小肠梗阻率更高,但与非放疗IBD队列比长期并发症无差异,直肠癌特异性死亡率相似,提示IBD不应排除放疗。
要点
- IBD合并直肠癌患者放疗期间中断与止泻药需求与无IBD患者无显著差异。
- 放疗联合IBD组小肠梗阻率显著更高,但与非放疗IBD队列比长期并发症无差异。
- 各队列直肠癌特异性死亡率相似,IBD不应成为放疗禁忌。
核心结论
- 放疗似乎不增加IBD合并直肠癌患者的急性或长期毒性,有指征时应视为标准治疗组成部分。
研究设计与样本
- 配对病例对照分析,纳入2000至2015年诊断的186例美国退伍军人直肠癌患者,其中71例IBD接受放疗、71例无IBD匹配对照接受放疗、44例IBD非匹配对照未接受放疗。
- 采用多变量逻辑回归、Fine-Gray和frailty模型分析短期与长期毒性及死亡,并校正潜在混杂因素。
主要发现
- 与非放疗IBD非匹配队列比较,长期并发症无差异;其他急性或长期毒性无差异;各队列直肠癌特异性死亡率相似。
临床怎么用
- 对有放疗指征的IBD合并直肠癌患者,不应因IBD而排除盆腔放疗。
- 放疗期间需关注IBD患者住院风险和小肠梗阻风险,但急性中断与止泻药需求未见显著增加。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inflammatory bowel disease (IBD) is a known risk factor for rectal cancer, and RT is often an important part of therapy for these patients. Previously published studies have raised concerns for increased rates of RT toxicity in patients with IBD. We performed a matched case-control analysis to assess RT-related toxicity in a large sample of U.S. veterans afflicted with IBD and rectal cancer. METHODS AND MATERIALS: We identified 186 veterans with rectal cancer (71 Patients with IBD treated with RT, 71 matched controls without IBD treated with RT, and 44 nonmatched controls with IBD treated without RT) diagnosed between 2000 and 2015. We analyzed short- and long-term toxicity and mortality in multivariable logistic regression, Fine-Gray, and frailty models, adjusting for potential confounders. RESULTS: When comparing patients with and without IBD treated with RT there were no differences in RT breaks (adjusted odds ratio [aOR], 1.70; 95% confidence interval [CI], 0.38-4.76; P = .49) or the need for antidiarrheal medication during RT (aOR, 1.53; 95% CI, 0.70-3.35; P = .29). There was a trend toward higher risk of hospital admission during RT for RT + patients with IBD (aOR, 2.69; 95% CI, 0.88-8.22; P = .08). There were higher rates of small bowel obstruction (OR, 15; 95% CI, 1.9-115; P = .009) and a trend toward higher rates of abdominopelvic adhesions (OR, 3.6; 95% CI, 0.98-13; P = .05) in the RT + IBD cohort. However, compared with a nonmatched cohort of patients with IBD treated without RT there were no differences in long-term complications. No differences were found in other acute or long-term toxicities. Rectal cancer-specific mortality appeared similar across all cohorts. CONCLUSIONS: RT does not appear to increase the rates of acute or long-term toxicity in patients with IBD and should be considered a standard part of therapy when otherwise indicated.
引用
- Mudgway R, Bryant AK, Heide ES, et al. A Matched Case-Control Analysis of Clinical Outcomes for Patients With Inflammatory Bowel Disease and Rectal Cancer Treated With Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 31461672. doi:10.1016/j.ijrobp.2019.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。